Eliminating METTL1-mediated accumulation of PMN-MDSCs prevents hepatocellular carcinoma recurrence after radiofrequency ablation.
Xuezhen ZengGuanrui LiaoShumin LiHaining LiuXiao ZhaoShuang LiKai LeiShenghua ZhuZhihang ChenYi ZhaoXuxin RenTianhong SuAlfred Sze-Lok ChengSui PengShuibin LinJi WangShuling ChenMing KuangPublished in: Hepatology (Baltimore, Md.) (2022)
Our study sheds light on the pivotal role of METTL1 in modulating an immunosuppressive microenvironment and demonstrated that interrupting METTL1-TGF-β2-PMN-MDSC axis could be a therapeutic strategy to restore antitumor immunity and prevent HCC recurrence after RFA treatment, meriting further clinical studies.